Cybin CEO AMA: Patents, DMT Trials, Timelines and Raising Capital in a Recession | CYBN Stock

Aldeyra braces for potential dry eye disease rejection after FDA says more data are necessary

Aldeyra Therapeutics is bracing for a potential rejection of reproxalap months after boldly touting its application as “the most comprehensive NDA package ever submitted for

October 17, 2023

Novo Nordisk sues unauthorized semaglutide compounders, tempers expectations for Wegovy’s global rollout

Novo Nordisk is striking back against illegal semaglutide compounders, filing an initial five lawsuits and preparing more in the coming days and weeks. The first

June 21, 2023

Attacks on emergency room workers prompt debate over tougher penalties

Patients hurl verbal abuse at Michelle Ravera every day in the emergency room. Physical violence is less common, she said, but has become a growing

April 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.